Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
Public ClinicalTrials.gov record NCT02345070. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study
Study identification
- NCT ID
- NCT02345070
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 327 participants
Conditions and interventions
Conditions
Interventions
- SAR156597 Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2015
- Primary completion
- May 21, 2017
- Completion
- Aug 13, 2017
- Last update posted
- Mar 23, 2022
2015 – 2017
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840003 | Phoenix | Arizona | 85006 | — |
| Investigational Site Number 840020 | Jacksonville | Florida | 32209 | — |
| Investigational Site Number 840022 | Loxahatchee Groves | Florida | 33470 | — |
| Investigational Site Number 840017 | Atlanta | Georgia | 30322 | — |
| Investigational Site Number 840008 | Decatur | Georgia | 30033 | — |
| Investigational Site Number 840010 | Louisville | Kentucky | 40218 | — |
| Investigational Site Number 840009 | Minneapolis | Minnesota | 55455 | — |
| Investigational Site Number 840006 | Rochester | Minnesota | 55905 | — |
| Investigational Site Number 840026 | Chesterfield | Missouri | 63017 | — |
| Investigational Site Number 840001 | Lebanon | New Hampshire | 03756 | — |
| Investigational Site Number 840002 | Summit | New Jersey | 07901 | — |
| Investigational Site Number 840015 | Jamaica | New York | 11435 | — |
| Investigational Site Number 840023 | Mineola | New York | 11501 | — |
| Investigational Site Number 840012 | New York | New York | 10016 | — |
| Investigational Site Number 840013 | Stony Brook | New York | 11794-8121 | — |
| Investigational Site Number 840014 | Philadelphia | Pennsylvania | 19104 | — |
| Investigational Site Number 840011 | Dallas | Texas | 75390 | — |
| Investigational Site Number 840024 | Everett | Washington | 98208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02345070, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02345070 live on ClinicalTrials.gov.